08:00 , Feb 11, 2013 |  BC Week In Review  |  Company News

Amorfix management update

Amorfix Life Sciences Ltd. (TSX:AMF), Mississauga, Ontario   Business: Diagnostic, Neurology   Hired: Warren Whitehead as CFO, formerly CFO of Arius Research Inc. , which Roche acquired; he replaces Janet Clennett, who becomes director of...
08:00 , Feb 22, 2010 |  BioCentury  |  Finance

Ebb & Flow

For its fourth global venture fund, Caduceus Private Investments IV, OrbiMed Advisors raised $550 million, making it the largest healthcare venture fund to be raised in almost a year. Last March, Essex Woodlands closed a...
07:00 , Aug 13, 2009 |  BC Innovations  |  Targets & Mechanisms

Eating away at leukemia

Researchers at Stanford University School of Medicine have found that acute myelogenous leukemia stem cells can exploit the cell-surface protein CD47 to avoid ingestion by macrophages. 1,2 They show that a mAb against CD47 increased...
07:00 , Sep 29, 2008 |  BC Week In Review  |  Company News

Arius, Roche deal

Roche completed its previously announced acquisition of antibody platform company Arius for about C$191 million (US$182.3 million) in cash (see BioCentury, July 28). Arius Research Inc. (TSX:ARI), Toronto, Ontario   Roche (SWX:ROG), Basel, Switzerland  ...
07:00 , Jul 28, 2008 |  BC Week In Review  |  Company News

Arius, Roche deal

Roche will acquire antibody platform company Arius for about C$191 million (US$190.7 million) in cash. The deal includes the purchase of Arius’ common shares at C$2.44 and the purchase of issued and outstanding warrants at...
07:00 , Jul 28, 2008 |  BioCentury  |  Finance

Ebb & Flow

For the second time this month, a sizeable first-time fund with a seasoned team has closed above its initial target. Last week, Cowen Healthcare Royalty Partners closed its first fund at more than $500 million....
01:28 , Jul 24, 2008 |  BC Extra  |  Company News

Roche to acquire Arius

Roche (SWX:ROG) will acquire Arius (TSX:ARI) for about C$191 million (US$190.7 million) in cash. The pharma company will pay C$2.44 per Arius share, which is a 15% premium to Arius' close of C$2.13 on Tuesday,...
07:00 , Jul 17, 2008 |  BC Innovations  |  Targets & Mechanisms

Cancer's Long-distance Plan

Researchers at the Massachusetts Institute of Technology have uncovered a new role for the endocrine factor osteopontin as a 'long-distance' modulator of tumor growth. Researchers polled by SciBX felt that the findings not only opened...
07:00 , May 1, 2008 |  BC Innovations  |  Tools & Techniques

Mimicking Mucins

Researchers have developed synthetic glycopolymers that model the binding behavior of mucins on the surfaces of living cells. The technique, which avoids the difficulties associated with studying mucins in their complex native state, could lead...
07:00 , Apr 21, 2008 |  BC Week In Review  |  Company News

Arius board of directors update

Arius Research Inc. (TSX:ARI), Toronto, Canada   Business: Cancer   Appointed: Graham Strachan, former president and CEO of Allelix Biopharmaceuticals Inc.   Retired: William Bodenhamer  ...